(DNTH)

Reporting relationship: Director
Issuer ticker: DNTH
Reported as of: 22 Jan 2024
Net transaction value: +$2,000,004
SEC form: 4
Accepted by SEC: 24 Jan 2024, 19:04:43 UTC
Prior SEC filing: 13 Sep 2023
Next SEC filing: 28 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Adam Veness, as attorney-in-fact for Leon O. Moulder Jr.

Key filing fact

Moulder Leon O Jr. filed Form 4 for Dianthus Therapeutics, Inc. /DE/ (DNTH) on 24 Jan 2024.

Key facts

This page summarizes Moulder Leon O Jr.'s Form 4 filing for Dianthus Therapeutics, Inc. /DE/ (DNTH).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Jan 2024, 19:04.

Change

Previous filing in this sequence was filed on 13 Sep 2023.
Current net transaction value: +$2,000,004.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DNTH transaction

Common Stock

Award

Transaction value: $2,000,004
Shares: +166,667
Change %: +13%
Price: $12.00
Shares after: 1,436,745
Date: 22 Jan 2024
Ownership: See footnote
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Consists of 166,667 shares of common stock purchased by Tellus BioVentures, LLC ("Tellus") from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Footnote F2

The securities reported are held of record by Tellus. The Reporting Person may be deemed to have voting and dispositive control over the shares held by Tellus. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.